63 research outputs found
Topics in cancer genomics
Large-scale projects such as the The Cancer Genome Atlas (TCGA) have generated extensive exome libraries across several disease types and populations. Detection of somatic changes in HLA genes by whole-exome sequencing (WES) has been complicated by the highly polymorphic nature of these loci. We developed a method POLYSOLVER (POLYmorphic loci reSOLVER) for accurate inference of class I HLA-A, -B and -C alleles from WES data, and achieved 97% accuracy at protein level resolution when this was applied to 133 HapMap samples of known HLA type. By applying POLYSOLVER in conjunction with somatic change detection tools to 2688 tumor/normal pairs TCGA that were previously analyzed by conventional approaches, we re-discovered 37 of 56 (66%) HLA mutations, while further identifying 23 new events. An analysis of WES data from a larger set of 3768 tumor/normal pairs by POLYSOLVER revealed 131 class I mutations with an enrichment for potentially loss-of-function events. 3% of samples had at least one HLA event with 95 of 131 mutations in the T cell interacting and peptide binding domains. Recurrent hotspot sites of missense, nonsense and splice site mutations were discovered that suggest positive selection, and support immune evasion as an important pathway in cancer.
Exome sequencing has also revealed a large number of shared and personal somatic mutations across human cancers. In principle, any genetic alteration affecting a protein-coding region has the potential to generate mutated peptides that are presented by surface HLA class I proteins that might be recognized by cytotoxic T cells. Utilizing POLYSOLVER in conjunction with knowledge of mutations in other genetic loci inferred from exome data, we developed a pipeline for the prediction and validation of such neoantigens derived from individual tumors and presented by patient-specific alleles of the HLA proteins. We applied our computational pipeline to 91 chronic lymphocytic leukemias (CLL) that had undergone whole-exome sequencing. We predicted ~22 mutated HLA-binding peptides per leukemia (derived from ~16 missense mutations), and experimentally confirmed HLA binding for ~55% of such peptides. Finally, we computationally predicted HLA-binding peptides with missense or frameshift mutations for several cancer types and predicted dozens to thousands of neoantigens per individual tumor, suggesting that neoantigens are frequent in most tumors. The neoantigen prediction pipeline can also elucidate the neoantigens unique to a particular cancer patient and help in the design of personalized immune vaccines.
MicroRNAs (miRs) are a class of non-coding small RNAs that regulate gene expression by promoting mRNA degradation or by inhibiting mRNA translation. Context Likelihood of Relatedness (CLR) is genetic network reconstruction method that considers the local network context in assessing the significance of connections while also allowing for detection of non-linear associations. Leveraging TCGA multidimensional data in glioblastoma, we inferred the putative regulatory network between microRNA and mRNA using the CLR algorithm. Interrogation of the network in context of defined molecular subtypes identified 8 microRNAs with a strong discriminatory potential between proneural and mesenchymal subtypes. Integrative in silico analyses, a functional genetic screen, and experimental validation identified miR-34a as a tumor suppressor in proneural subtype glioblastoma. Mechanistically, in addition to its direct regulation of platelet-derived growth factor receptor-alpha (PDGFRA), promoter enrichment analysis of CLR-inferred mRNA nodes established miR-34a as a novel regulator of a SMAD4 transcriptional network. Clinically, miR-34a expression level is shown to be prognostic, where miR-34a low-expressing glioblastomas exhibited better overall survival. This work illustrates the potential of comprehensive multidimensional cancer genomic data combined with computational and experimental models to enable mechanistic exploration of relationships among different genetic elements across the genome space in cancer
Generating Artificial Antigen Presenting Cells for Adoptive T-Cell Therapy
https://openworks.mdanderson.org/sumexp22/1104/thumbnail.jp
Recommended from our members
Integrative functional genomics identifies RINT1 as a novel GBM oncogene
Large-scale cancer genomics efforts are identifying hundreds of somatic genomic alterations in glioblastoma (GBM). Distinguishing between active driver and neutral passenger alterations requires functional assessment of each gene; therefore, integrating biological weight of evidence with statistical significance for each genomic alteration will enable better prioritization for downstream studies. Here, we demonstrate the feasibility and potential of in vitro functional genomic screens to rapidly and systematically prioritize high-probability candidate genes for in vivo validation. Integration of low-complexity gain- and loss-of-function screens designed on the basis of genomic data identified 6 candidate GBM oncogenes, and RINT1 was validated as a novel GBM oncogene based on its ability to confer tumorigenicity to primary nontransformed murine astrocytes in vivo. Cancer genomics-guided low-complexity genomic screens can quickly provide a functional filter to prioritize high-value targets for further downstream mechanistic and translational studies
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
Detection of somatic mutations in human leukocyte antigen (HLA) genes using whole-exome sequencing (WES) is hampered by the high polymorphism of the HLA loci, which prevents alignment of sequencing reads to the human reference genome. We describe a computational pipeline that enables accurate inference of germline alleles of class I HLA-A, B and C genes and subsequent detection of mutations in these genes using the inferred alleles as a reference. Analysis of WES data from 7,930 pairs of tumor and healthy tissue from the same patient revealed 298 nonsilent HLA mutations in tumors from 266 patients. These 298 mutations are enriched for likely functional mutations, including putative loss-of-function events. Recurrence of mutations suggested that these \u27hotspot\u27 sites were positively selected. Cancers with recurrent somatic HLA mutations were associated with upregulation of signatures of cytolytic activity characteristic of tumor infiltration by effector lymphocytes, supporting immune evasion by altered HLA function as a contributory mechanism in cancer
Recommended from our members
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain incompletely characterized and have yet to be validated in large cohorts. By analyzing longitudinal tumor biopsies from 17 metastatic melanoma patients treated with CPB therapies, we observed point mutations, deletions or loss of heterozygosity (LOH) in beta-2-microglobulin (B2M), an essential component of MHC class I antigen presentation, in 29.4% of patients with progressing disease. In two independent cohorts of melanoma patients treated with anti-CTLA4 and anti-PD1, respectively, we find that B2M LOH is enriched threefold in non-responders (~30%) compared to responders (~10%) and associated with poorer overall survival. Loss of both copies of B2M is found only in non-responders. B2M loss is likely a common mechanism of resistance to therapies targeting CTLA4 or PD1
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
As tumors grow, they acquire mutations, some of which create neoantigens that influence the response of patients to immune checkpoint inhibitors. We explored the impact of neoantigen intratumor heterogeneity (ITH) on antitumor immunity. Through integrated analysis of ITH and neoantigen burden, we demonstrate a relationship between clonal neoantigen burden and overall survival in primary lung adenocarcinomas. CD8(+) tumor-infiltrating lymphocytes reactive to clonal neoantigens were identified in early-stage non–small cell lung cancer and expressed high levels of PD-1. Sensitivity to PD-1 and CTLA-4 blockade in patients with advanced NSCLC and melanoma was enhanced in tumors enriched for clonal neoantigens. T cells recognizing clonal neoantigens were detectable in patients with durable clinical benefit. Cytotoxic chemotherapy–induced subclonal neoantigens, contributing to an increased mutational load, were enriched in certain poor responders. These data suggest that neoantigen heterogeneity may influence immune surveillance and support therapeutic developments targeting clonal neoantigens
The somatic genomic landscape of glioblastoma
We describe the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors, including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer
The Somatic Genomic Landscape of Glioblastoma
We describe the landscape of somatic genomic alterations based on multi-dimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs). We identify several novel mutated genes as well as complex rearrangements of signature receptors including EGFR and PDGFRA. TERT promoter mutations are shown to correlate with elevated mRNA expression, supporting a role in telomerase reactivation. Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM. Integrative analysis of genomic and proteomic profiles challenges the notion of therapeutic inhibition of a pathway as an alternative to inhibition of the target itself. These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations and the generation of unanticipated hypotheses that can advance our molecular understanding of this lethal cancer
- …